Blackstone to sell Japan supplement maker Alinamin to MBK for 350 billion yen: source
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
PRIVATE equity firm Blackstone is nearing a deal to sell Japanese supplement maker Alinamin Pharmaceutical to North Asian buyout fund MBK Partners for 350 billion yen (S$2.9 billion), a source with direct knowledge of the matter said on Tuesday (Jul 2).
The deal is expected to be signed soon, said the source, who declined to be identified as the information was private.
MBK, Blackstone and Alinamin declined to comment.
Blackstone had agreed in August 2020 to acquire Alinamin, then a subsidiary of Takeda Pharmaceutical, according to an announcement from the private equity firm at the time.
Nikkei first reported Blackstone’s planned sale of Alinamin earlier on Tuesday.
MBK aims to use its experience in consumer goods acquisitions to boost Alinamin’s value, the Nikkei reported.
Navigate Asia in
a new global order
Get the insights delivered to your inbox.
Previously known as Takeda Consumer Healthcare, Alinamin provides over-the-counter medicines in Japan.
After Blackstone’s takeover, the company set up a unit in Taiwan and increased its overseas sales, the Nikkei reported. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
‘Boring’ is the new black: The stars are aligning for a Singapore stock market revival
Near sell-out launches in March boost developer sales to 1,300 units after four slow months
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Genting Singapore’s Lim Kok Thay receives S$7.5 million pay package for FY2025
